Description: Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of a therapeutic agent for the treatment of alcohol use disorder (AUD). Its lead drug product is AD04. AD04 is a selective serotonin-3 antagonist. AD04 can also be used for the treatment of other addictive disorders, such as obesity, smoking, and drug addiction. The Company has completed a Phase-II clinical trials of AD04.
Home Page: www.adialpharma.com
ADIL Technical Analysis
1180 Seminole Trail
Charlottesville,
VA
22901
United States
Phone:
434 422 9800
Officers
| Name | Title |
|---|---|
| Mr. Cary John Claiborne MBA | CEO, Pres & Director |
| Mr. Joseph A. M. Truluck M.B.A., MBA | CFO, Treasurer & Sec. |
| Dr. Bankole A. Johnson DSc, FRCPsych, M.D., M.Phil, Ph.D. | Founder & Chief Medical Officer |
| Mr. John R. Martin J.D. | Gen. Counsel |
| Mr. Alex Lugovoy | Chief Bus. Officer |
| Dr. Jack W. Reich Ph.D. | Head of Regulatory |
| Mr. Mark H. Peikin | Chief Strategy Officer & Chief Devel. Officer |
| Mr. Lawrence Goldman CPA | Controller |
| Ms. Catherine Fratila | Controller |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.1791 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2018-07-30 |
| Fiscal Year End: | December |
| Full Time Employees: | 16 |